ACIP Presentation Slides: February 22-24, 2023 Meeting

At a glance

  • Note: These files are not yet 508
  • Slides will be added as they become available.

February 22, 2023

Welcome & Introductions

Introduction

Dr. G Lee

Dr. M Wharton

Mpox Vaccine

Introduction [16 pages]

Dr. Pablo Sanchez

Epidemiology of mpox during 2022 outbreak in the United States [18 pages]

Dr. Sascha Ellington

JYNNEOS Vaccine Safety [26 pages]

Dr. Jonathan Duffy

JYNNEOS Vaccine Effectiveness [21 pages]

Dr. Anna Chard

Mpox vaccine acceptability and uptake from cross-sectional surveys [26 pages]

Dr. Kevin P. Delaney

Interim Clinical Considerations [12 pages]

Dr. Rosalind Carter

EtR: Use of JYNNEOS during mpox outbreaks [48 pages]

Dr. Agam Rao

Respiratory disease surge, Fall 2022, United States

Dr. José R. Romero

Influenza Vaccine

Introduction [3 pages]

Dr. Keipp Talbot

U.S. Influenza activity update [7 pages]

Dr. Lisa Grohskopf

Preliminary 2022-23 influenza vaccine effectiveness: CDC networks [25 pages]

Ms. Samantha Olson, Dr. Nathaniel Lewis, Dr. Mark Tenforde

Preliminary 2022-23 influenza vaccine effectiveness: Wisconsin [15 pages]

Dr. Huong McClean

Published Estimates of LAIV Effectiveness [4 pages]

Dr. Lisa Grohskopf

Pneumococcal Vaccines

Introduction [9 pages]

Dr. Katherine Poehling

Epidemiology of pneumococcal disease among U.S. children [21 pages]

Mr. Ryan Gierke

Estimating the impact of higher-valency PCVs on pediatric outpatient ARI visits and antibiotic use [27 pages]

Ms. Laura King

PCV20 Phase 2/3 study results among children [18 pages]

Dr. Wendy Watson

Preliminary EtR (incl. GRADE) for PCV20 use in U.S. children [57 pages]

Dr. Miwako Kobayashi

Workgroup considerations [12 pages]

Dr. Miwako Kobayashi

February 23, 2023

Welcome & Introductions

Introduction

Dr. G Lee

Dr. M Wharton

Agency Updates

Meningococcal Vaccines

Introduction [8 pages]

Dr. Kathy Poehling

Epidemiology of meningococcal disease in the United States [17 pages]

Ms. Amy Rubis

Pfizer pentavalent meningococcal vaccine [26 pages]

Dr. Jason Maguire

Workgroup considerations [15 pages]

Dr. Sam Crowe

Polio Vaccine

Introduction [2 pages]

Dr. Oliver Brooks

Recommendations for Adult Polio Vaccination [29 pages]

Dr. Sarah Kidd

RSV Vaccines – Pediatric/Maternal

Introduction [5 pages]

Dr. S Long

Cost effectiveness analysis for nirsevimab – CDC model [40 pages]

Dr. David Hutton

Cost effectiveness analysis for nirsevimab – Comparison to manufacturer model [23 pages]

Dr. Ismael Ortega Sanchez

Evidence to Recommendations framework for nirsevimab [92 pages]

Dr. Jefferson Jones

Clinical considerations for nirsevimab [16 pages]

Dr. Jefferson Jones

Safety and Efficacy of RSV Bivalent PreF Maternal Vaccine [31 pages]

Dr. Iona Munjal

Workgroup considerations [6 pages]

Dr. Katherine Fleming-Dutra

RSV Vaccines – Adult

Introduction [8 pages]

Dr. Camille Kotton

Cost effectiveness of the GSK and Pfizer vaccines (main CDC model) [37 pages]

Dr. David Hutton

Comparison of cost effectiveness results of the main CDC model and each manufacturer model (GSK & Pfizer) [24 pages]

Dr. Ismael Ortega Sanchez

EtR (incl. GRADE) for 2 vaccines (GSK & Pfizer) [90 pages]

Dr. Michael Melgar

Vaccine policy questions (GSK & Pfizer) [2 pages]

Dr. Michael Melgar

Chikungunya Vaccine

Introduction [7 pages]

Dr. Beth Bell

Global epidemiology of chikungunya [12 pages]

Dr. Susan Hills

Chikungunya in U.S. travelers [15 pages]

Ms. Nicole Lindsey

Persistent arthralgia following chikungunya [21 pages]

Ms. Nicole Lindsey

Workgroup considerations [4 pages]

Ms. Nicole Lindsey

Dengue Vaccines

Introduction [8 pages]

Dr. W Chen

Takeda dengue vaccine (TAK-003) safety and efficacy [26 pages]

Dr. Shibidas Biswal

Workgroup considerations [22 pages]

Dr. Gabriela Paz-Bailey

Varicella

Public health impact of 25 years of varicella vaccination in the United States [23 pages]

Dr. Mona Marin